RecruitingPhase 2NCT06760819
Rare condition
Salivary gland type cancer of the breast
7
studies recruiting now
as of 7 Sept 2026
54
studies registered in total
as of 7 Sept 2026
13
countries with a recruiting site
as of 7 Sept 2026
7 Jan 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT06695845
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RecruitingNCT02012699
Integrated Cancer Repository for Cancer Research
RecruitingPhase 1NCT04969835
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
RecruitingPhase 2NCT06638931
Agnostic Therapy in Rare Solid Tumors
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 7 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Salivary gland type cancer of the breast study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Salivary gland type cancer of the breast
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
15 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 2Cisplatin (Cisplatin)
Phase 2Cabozantinib
Phase 2Nintedanib (Nintedanib component of ofev)
Phase 2Paclitaxel (Abraxane)
Phase 2Ipilimumab (Yervoy)
Phase 2Eribulin Mesylate (Eribulin baxter)
Phase 2Carboplatin (Carboplatin)
Phase 2Axitinib (Inlyta)
+ 7 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).